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Sickness  behavior  appears  to be the  expression  of a  central  motivational  state  that  reorganizes  the  organ-
ism’s  priorities  to  cope  with  infectious  pathogens.  To  evaluate  the  effect  of  dipyrone  in  lipopolysaccharide
(LPS)-induced  sickness  behavior,  mice  were  subjected  to  the  forced  swim  test  (FST),  tail  suspension  test
(TST),  dark–light  box  test,  open  ﬁeld  test,  sucrose  preference  intake  test  and  food  intake  test.  LPS  admin-





depressed  locomotor  activity  in the  open  ﬁeld  test.  Treatment  with  LPS  decreased  the  total  number  of
transitions  made  between  the  dark  and  light  compartments  of  the  apparatus  and  induced  anhedonia  and
anorexia.  Pre-treatment  with  dipyrone  (10,  50,  or 200  mg/kg)  attenuated  behavioral  changes  induced
by  LPS  in the  FST,  TST,  open  ﬁeld  and  light–dark  box  tests.  In  addition,  dipyrone  prevented  anhedonia
and  anorexia  in mice  challenged  with  LPS.  Considering  that  dipyrone  attenuates  LPS-induced  behavioral
changes,  it is  proposed  that  LPS-induced  sickness  behavior  is  dependent  on  the  COX  pathway.. Introduction
Sickness behavior is the expression of a motivational state trig-
ered by an activation of the peripheral innate immune system
nd is characterized by depressive-like behavior, such as a reduc-
ion in locomotor activity and exploratory behavior, anorexia and
nhedonia [7,17]. The mechanisms underlying sickness behavior
ave not been fully elucidated, but it has been suggested that
ytokines and prostaglandins are involved [7,9,17,30]. Interleukin-
, interleukin-6 and tumor necrosis factor- (TNF-) may  be
ecreted in response to infections and endotoxemia [7,17]. Previ-
us reports have demonstrated that LPS-induced depressive-like
ehavior appears to depend on the cyclooxygenase (COX) path-
ay as the use of a non-steroidal anti-inﬂammatory drug (NSAID)
indomethacin and nimesulide) has been shown to attenuate the
ehavioral changes induced by LPS [9]. COX is the key enzyme in
he synthesis of prostaglandins from arachidonic acid. While COX-
 is a constitutive enzyme, COX-2 is induced by several stimuli,
nd the biosynthesis of both is inhibited by NSAIDs [31]. The pyra-
olone derivative dipyrone, also known as metamizole, is an NSAID
hat acts as an effective analgesic and antipyretic and has been
emonstrated to inhibit COX [25].
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In contrast to classical NSAIDs, dipyrone produces anal-
gesic effects associated with a less potent anti-inﬂammatory
action in different animal models [15]. There are four major
metabolites of dipyrone, but only the main metabolites, 4-methyl-
amino-antipyrine (MAA) and 4-amino-antipyrine (AA), alter the
biochemical properties of COX [25]. Considering the difference in
the mechanism of action between dipyrone and the nonsteroidal
anti-inﬂammatory drugs and the popularity of dipyrone as an
analgesic and antipyretic drug during infective illnesses in many
countries, the aim of the present study was to investigate the effects
of pre-treatment with dipyrone on LPS-induced sickness behavior.
2. Materials and methods
2.1.  Animals
Adult male Swiss mice (25–30 g), obtained from the Central
Facility of the Federal University of Alfenas, were individually
housed, for at least a week, in a room controlled temperature
(24 ± 1 ◦C), humidity (40–60%) and a 12:12 h light–dark cycle (lights
off at 6:00 pm). Standard rodent chow and tap water were provided
ad libitum throughout the experiments except where indicated. Dif-
ferent animals were used for each experiment. Immediately after
the end of the experiments, the animals were euthanized with
Open access under the Elsevier OA license.halothane overdose so as to avoid any suffering.
All procedures were conducted in accordance with the Declara-
tion of Helsinki on the welfare of experimental animals and with






















































and 200 mg/kg) signiﬁcantly reversed the anorexic effect induced
by LPS at 2 h (F4,39 = 7.3; p < 0.002), 4 h (F4,39 = 13.84; p < 0.001), 6 h
(F4,39 = 13.89; p < 0.001) and 24 h (F4,39 = 7.17; p < 0.001).R. Soncini et al. / Neuroscie
lfenas-MG (protocol number: 167/2008). All behavioral tests were
onducted by an experimenter blind to the treatment groups.
.2.  Depressive-like and exploratory behavior
Mice were pre-treated with dipyrone (10, 50 or 200 mg/kg, i.p.)
r vehicle (sterile saline, 0.9% NaCl, 1 ml/kg) 30 min  before injection
f LPS extracted from Escherichia coli serotype 026:B6 (200 g/kg,
.p.; at 12:00 pm) or sterile saline (0.9% NaCl). The behavioral tests
ncluded the forced swimming test (FST), tail suspension test (TST),
ight–dark box test and open ﬁeld test all of which were performed
20 min  after LPS administration (for details, see Ref. [9]). The
xperiments were recorded using a video camera.
.2.1. Forced swimming test (FST)
Mice (n = 12 per group) were placed in a vertical glass cylinder
26 cm high, 12 cm in diameter) ﬁlled with 25 ◦C water to a depth of
6 cm.  For testing, each mouse was placed in the cylinder for 6 min
nd the duration of ﬂoating (i.e., the time during which mice made
nly the smallest movements necessary to keep their heads above
ater) was scored [9] from the ﬁlm.
.2.2. Tail suspension test (TST)
The mice (n = 8 per group) were suspended 50 cm above the ﬂoor
y adhesive tape placed approximately 1 cm from the tip of the tail.
mmobility time was recorded during a 6 min  period. The procedure
as modiﬁed from Dunn and Swiergiel [10].
.2.3. Light–dark box test
The  apparatus consisted of a rectangular Plexiglas box (48 cm
ong × 24 cm wide × 24 cm high) divided into a dark and light region
both 24 cm long). The light and dark regions were separated by an
pening (8 cm × 8 cm)  that allowed the animals to move between
he two compartments. The dark region was made of black Plex-
glas and covered with a black lid. The light portion was made of
hite Plexiglas with a 60 W light positioned directly over it. The
ice (n = 10 per group) were placed in the light compartment and
llowed to move freely between the two compartments. Behavior
as recorded for a total of 5 min  and scored for latency to the ﬁrst
ransition and the number of transitions between the light and dark
ompartments [9].
.2.4.  Open ﬁeld behavioral test
Locomotor activity was recorded for 5 min  in an open ﬁeld con-
isting of a 60 cm × 60 cm white Plexiglas box with its ﬂoor divided
nto 16 squares. Four squares were deﬁned as the center, and the
2 squares along the walls were considered the periphery. Each
ouse (n = 10 per group) was gently placed exactly in the center of
he box, and activity was scored as a line crossing when a mouse
emoved all four paws from one square and entered another. Line
rossings among the central four squares or among the peripheral
2 squares of the open ﬁeld were counted separately [9,10].
.3.  Sucrose preference intake test
Animals received food and water ad libitum and had access to
0% sucrose for 2 h every day (2:00–4:00 pm)  for ﬁve days (sucrose
ntake training). After this period, to establish LPS doses that could
roduce a pronounced anhedonic behavior, doses of LPS (200,
00 or 1000 g/kg, i.p.; n = 10 animals per group) or saline were
njected at 12:00 pm. At 2:00 pm,  mice had access to water and
0% sucrose for 24 h. This experiment was designed to assess the
ffect of LPS on the preference for a palatable solution using a two-
ottle paradigm in which mice could choose between a bottle of
ater and a bottle containing a sucrose solution. The ﬂuid intake
as measured by weighing water and sucrose bottles at 2 andtters 516 (2012) 114– 118 115
24  h. Another set of mice (n = 10 animals per group) received injec-
tions of dipyrone or saline 30 min  prior to LPS (1000 g/kg) both
administered at 12:00 pm.  At 2:00 pm,  mice had access to water
and 10% sucrose for 24 h. Fluid intake was  measured by weighing
the water and sucrose bottles at 2 and 24 h. Sucrose preference was
determined using the following equation: sucrose intake/total ﬂuid
intake (water + sucrose intake) × 100 [18].
2.4.  Food intake
Mice  were weighed and assigned arbitrarily to body weight-
matched groups and were deprived of food for 24 h but still had
free access to tap water. On the following day, the animals received
injections of dipyrone (n = 6 animals) or saline (i.p., n = 13 ani-
mals) and 30 min  later (around to 12:00 pm)  were administered an
injection of LPS (100 g/kg, i.p.) or saline (i.p). Immediately after,
pre-weighed chow pellets were offered to the animals. Food intake
was measured at 2, 4, 6 and 24 h by weighing the remaining food
pellets along with any spillage into the cage.
2.5. Statistical analysis
The  results are reported as the mean ± S.E.M. Analysis of vari-
ance (ANOVA) followed by the Newman–Keuls test was used for
comparisons. Differences were considered signiﬁcant at p < 0.05.
3.  Results
There was an increase in the immobility period 120 min  after
the administration of LPS in the FST (F4,39 = 27.3; p < 0.001; Fig. 1A)
and TST (F4,39 = 19.4; p < 0.001; Fig. 1B) in mice pre-treated with
vehicle. Pre-treatment with dipyrone signiﬁcantly reversed the
LPS-mediated increase in the immobility period in both the FST
(at doses of 10, 50 and 200 mg/kg) and TST (at doses of 50 and
200 mg/kg). Furthermore, there was a signiﬁcant reduction in the
number of transitions between the light and dark compartments
after LPS administration. The pretreatment with dipyrone (50 and
200 mg/kg) prior to LPS administration caused a greater number
of transitions between the compartments compared to the vehi-
cle plus LPS group (F4,39 = 89.6; p < 0.001; Fig. 1C). In addition,
LPS signiﬁcantly decreased the number of line crossings in the
center and periphery as well as the total number of line cross-
ings. Post hoc analyses indicated that pre-treatment with dipyrone
signiﬁcantly reversed LPS-induced decreases in the number of cen-
tral (F4,39 = 129.7; p < 0.001; Fig. 1D) and peripheral line crossings
(F4,39 = 143.2; p < 0.001; Fig. 1E) as well as the total number of line
crossings (F4,39 = 224.5; p < 0.001; Fig. 1F).
The 1000 g/kg dose of LPS reduced sucrose preference at 2 h
(F3,35 = 3.44; p < 0.05) and 24 h (F3,35 = 6.71; p < 0.0012) when com-
pared to the control group (Fig. 2). After 2 h (F4,55 = 2.68; p < 0.041)
and 24 h (F4,55 = 7.49; p < 0.001), the dipyrone plus LPS group
reestablished the sucrose preference as observed in the control
group (Fig. 3).
Compared to the control group, LPS signiﬁcantly depressed
food intake 2, 4, and 6 h after injection as well as overnight food
intake (Fig. 4). Pre-treatment with dipyrone (at doses of 10, 50The  animals that received dipyrone plus vehicle (saline), regard-
less of dose, showed no signiﬁcant differences in food intake
or sucrose preference in relation to the control group (data not
shown).
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Fig. 1. Effects of pre-treatment with dipyrone (10, 50 or 200 mg/kg) or vehicle associated with the administration of either lipopolysaccharide (LPS) or saline on behavioral
tests. Floating time in the forced swim test (FST; A), immobility time in the tail suspension test (TST; B), number of transitions in the light–dark box test (C); central (D),












































200 50 0 100 0Saline
LPS  (µg/kg)eripheral (E) and total (F) line crossings in the open ﬁeld test in mice. Results are sho
ith  control groups and #p < 0.05 when compared with the vehicle + LPS group.
. Discussion
The present results show that dipyrone administered prior to
ipopolysaccharide (LPS) attenuates exploratory behavior and loco-
otor activity and the anorexia and anhedonia caused by LPS
dministration, suggesting a possible involvement of cyclooxyge-
ase and subsequent release of prostaglandin E2 (PGE2) in sickness
ehavior.
Reduction in food intake is one of the hallmark symptoms
bserved after activation of the immune system. Injection of LPS or
ytokines results in decreases in food intake [5,20]. Direct action
ia central signaling mechanisms is better substantiated for the
ole of pro-inﬂammatory cytokines in illness anorexia than periph-
ral action on afferent nerves [1]. Cytokines may act directly on
euronal receptors, either through active transport across the
lood–brain barrier [2] or after passive diffusion into the circum-
entricular organs [12]. However, further evidence has indicated
hat non-neural cells of the blood–brain barrier, i.e., endothelial
ells and perivascular cells such as astrocytes and microglia, are
he most important sites of LPS and cytokine action in illness
norexia mediated by prostaglandins [1,9,23]. Several lines of evi-
ence indicate that PGE2 potently inhibits eating [1,19,20], andFig. 2. Preference for 10% sucrose solution 2 and 24 h after lipopolysaccharide (LPS;
200, 500 or 1000 g/kg) or vehicle administration in mice. Results are shown as the
mean ± S.E.M. The symbol denotes signiﬁcance level: *p < 0.05 when compared with
the saline group.
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cssociated  with the administration of either lipopolysaccharide (LPS) or saline on
reference for 10% sucrose solution. Results are shown as the mean ± S.E.M. The
ymbol denotes signiﬁcance level: *p < 0.05 when compared with the saline group.
njection of LPS or IL- increases COX-2 and mPGES-1 expres-
ion in brain endothelial cells [24]. Considering the present results,
nhibition of PGE production by dipyrone is a compelling argu-
ent for explaining the reversal of the LPS effect on food intake.
n addition, the anorectic response to IL-1 has been shown to
e absent or greatly attenuated in mice with a deletion of the
tges gene, which encodes the microsomal prostaglandin E syn-
hase (mPGES). These results suggest that IL-1-induced anorexia is
ainly prostaglandin-dependent and is most likely mediated by a
echanism similar to the one that is critical for febrile responses
6,11].
The present study conﬁrms previous observations that LPS can
nduce depressive-like behavior and a reduction in exploratory
ehavior in mice [9,10,30]. The doses the LPS change with the
xperimental models to distinguish and highlight the effects of LPS
n each experimental model. It also shows that these effects can
e reversed by pre-treatment with dipyrone. LPS administration
ncreased ﬂoating time in the FST, increased immobility time in
he TST, and depressed locomotor activity in the open ﬁeld test.
he light–dark test is based on a natural situation where an ani-
al is exposed to an unfamiliar environment. This test utilizes the
6 Veh icle + Sali ne
V hi l LPS
4
e c e + 
Dipyrone  (10 mg/kg)  + LPS
Dipyrone  (50 mg/kg)  + LPS

























ig. 4. Effects of pre-treatment with dipyrone (10, 50 or 200 mg/kg) or vehicle asso-
iated with the administration of either lipopolysaccharide (LPS) or saline on food
ntake in mice. Results are shown as the mean ± S.E.M. The symbols denote sig-
iﬁcance levels: *p < 0.05 when compared with control groups and #p < 0.05 when
ompared  with the vehicle + LPS group.tters 516 (2012) 114– 118 117
animal’s innate preference for the dark and avoidance of bright
spaces to assess anxiety-related behaviors [3]. In addition to illness,
LPS elicited an anxiogenic-like response in the light–dark box test,
characterized by a decrease in the number of transitions between
the dark and light compartments of the apparatus [10]. Teeling et al.
previously related the behavioral changes induced by LPS in the
burrowing and open ﬁeld tests to PGE2 in the brain [30]. Further-
more, de Paiva et al. provided evidence that prostaglandin synthesis
is necessary for the development of depressive-like and exploratory
behavior in mice as COX inhibitors also abolished this response and
decreased LPS-induced behaviors [9].
In addition to its ability to increase the duration of immobil-
ity in the forced swim test and the tail suspension test and to
reduce exploration in the light–dark box and open ﬁeld tests, LPS
also depressed sucrose consumption in the sucrose preference test.
Blunted sucrose intake in this test has been proposed to reﬂect
impaired sensitivity to reward and to model anhedonia, a core
symptom of major depression [8]. The present data demonstrate
that the LPS-induced anhedonic behavior was reversed by treat-
ment with dipyrone. Injections of LPS or the individual cytokines
themselves resulted in a reduction in food intake and a reduction in
the intake of palatable substances such as sucrose [5] and saccharin
[8]. In the present work, we  examined the anhedonic behavior in
mice using different doses of LPS and a 10% sucrose solution. For all
LPS doses tested, we  observed an interaction between inﬂamma-
tion and sickness behavior.
The  importance of COX in depressive pathology is highlighted
by recent ﬁndings demonstrating that the inﬂammatory enzyme
mediates many of the central effects of psychologically relevant
stressors [21,22] and that peripheral application of LPS serves as a
model for major depression [26]. It has been reported that chronic
treatment with celecoxib, a selective COX-2 inhibitor, reverses
chronic, unpredictable stress-induced depressive-like behavior by
reducing COX-2 expression in the rat brain [14]. COX-2-selective
NSAIDs, developed to reduce the burden of gastrointestinal toxic-
ity, raise concerns about cardiovascular safety through an unknown
mechanism [13]. On the other hand, non-selective COX-inhibitors
are anti-inﬂammatory, analgesic and also cause gastrointestinal
toxicity. Furthermore, Hinz et al. [15] showed that the major
metabolite of dipyrone, MAA, elicits a pronounced inhibition of
both COX-1 and COX-2 in vitro and ex vivo in the blood of patients
treated with clinically recommended dipyrone doses. After oral
administration of dipyrone, rapid occurrence of relevant MAA
plasma levels as early as 15 min  post administration, inhibition
of either isoform showed a virtually instantaneous onset even.
Dipyrone, in contrast to classical COX-inhibitors, has a low gas-
trointestinal toxicity, indicating a different mode of action [25].
Dipyrone has been postulated to act centrally through the inhi-
bition of COX-3, a variant of COX-1; however, the mechanism of
action of pyrazolone drugs is unknown [2,27]. Previous studies have
shown COX-3 to be sensitive to drugs that are analgesic/antipyretic
but which have low anti-inﬂammatory activity. Dipyrone inhibits
COX-3 with an IC50 value 6-fold lower than COX-1 but shows no
detectable inhibition of COX-2 [4].
Dipyrone has been blamed for causing agranulocytosis.
Although  it appears to be a statistically signiﬁcant effect, the inci-
dence is extremely low (1 case per million treatment periods)
[15,16]. However, more clinical investigation is necessary with
dipyrone. In animals, studies suggesting a minor anti-inﬂammatory
action of dipyrone compared with NSAIDs [29] have yet to be
addressed in humans [15]. Dipyrone is a drug widely used in
Latin America, Germany and several European countries. Preclinical
reports have shown that dipyrone acutely enhances morphine-
induced antinociception [28].
In summary, pre-treatment with dipyrone attenuated behav-
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ith LPS, suggesting that LPS-induced sickness behavior is depen-
ent on the COX pathway.
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